ARMP (Armata Pharmaceuticals) 1-Year Sharpe Ratio: 1.59 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARMP Armata Pharmaceuticals Inc ARMP
27 GF Score
Price $3.99
! 3 Warning Signs
View Full Analysis

What is Armata Pharmaceuticals 1-Year Sharpe Ratio?

Armata Pharmaceuticals ARMP +1.79% 27 1-Year Sharpe Ratio is 1.59 as of Jul. 15, 2026. GuruFocus rates ARMP with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-15), Armata Pharmaceuticals's 1-Year Sharpe Ratio is 1.59.

Armata Pharmaceuticals  (AMEX:ARMP) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Armata Pharmaceuticals 1-Year Sharpe Ratio Related Terms

ARMP vs NAGE, ALXO, LYEL: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Armata Pharmaceuticals's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Armata Pharmaceuticals 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's 1-Year Sharpe Ratio falls into.


ARMP
27GF Score
Armata Pharmaceuticals Inc ARMP
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Armata Pharmaceuticals 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 1.59 mean?
Armata Pharmaceuticals (ARMP) has a 1-Year Sharpe Ratio of 1.59 as of Jul. 15, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Armata Pharmaceuticals and its competitors.
Is Armata Pharmaceuticals' 1-Year Sharpe Ratio too high?
Armata Pharmaceuticals' current 1-Year Sharpe Ratio is 1.59. Overall, Armata Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Armata Pharmaceuticals' 1-Year Sharpe Ratio compare to NAGE and ALXO?
Armata Pharmaceuticals' 1-Year Sharpe Ratio of 1.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Armata Pharmaceuticals and its competitors. Armata Pharmaceuticals's current 1-Year Sharpe Ratio is 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Armata Pharmaceuticals stock overvalued right now?
Armata Pharmaceuticals (ARMP) has a current 1-Year Sharpe Ratio of 1.59. The current 1-Year Sharpe Ratio is 1.59. Armata Pharmaceuticals' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Armata Pharmaceuticals (ARMP), the current 1-Year Sharpe Ratio is 1.59 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Armata Pharmaceuticals Business Description

Other Exchanges TG1N:Germany
Address 5005 McConnell Avenue, Los Angeles, CA, USA, 90066
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
27GF Score

Get the complete analysis for ARMP

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.99
Price